Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02698670 · ClinicalTrials.gov registry record
Prospective Registry on User Experience With The Mapping System For Ablation Procedures
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 577
- Enrollment target
NCT02698670: Completed study, sponsored by Boston Scientific Corporation.
NCT02698670 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 577 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02698670 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 577 participants
- Enrollment target
Study Summary
This is an observational, prospective, non-randomized, multicenter, post approval study being conducted in the United States, Europe and Asia-Pacific Regions.
Primary Outcome
Primary endpoint is the acute procedural success for the primary arrhythmia in the whole cohort of ablation procedures. A procedure will be defined successful if all the following conditions will occur during the case: 1) ability to map, 2) completion of the necessary ablation applications, 3) primary arrhythmia termination (when applicable), and 4) validation of ablation through appropriate technique(s).
Interventions
- DEVICE Rhythmia mapping system
- DEVICE IntellaMap Orion mapping catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 577 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2017-05 |
What the finished NCT02698670 record still lists
NCT02698670 is an observational study that tracks outcomes without assigning an intervention. The registered 577 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Rhythmia mapping system is the first listed.
NCT02698670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02698670 about?
NCT02698670 is a clinical study titled "Prospective Registry on User Experience With The Mapping System For Ablation Procedures". This is an observational, prospective, non-randomized, multicenter, post approval study being conducted in the United States, Europe and Asia-Pacific Regions.
What is the current status of trial NCT02698670?
This trial is currently completed. The enrollment target is 577 participants. The study started on 2016-05-25. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02698670?
The interventions under investigation include: Rhythmia mapping system (DEVICE), IntellaMap Orion mapping catheter (DEVICE).
Who is sponsoring clinical trial NCT02698670?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07290543 · 578 participants · NA
Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI